Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis

Journal of Medicinal Chemistry

Volumn 55, Issue 24, 2012, Pages 10863-10884

  Chang, Dong Jo ^a   An, Hongchan ^a   Kim, Kyoung Suk ^a   Kim, Hyun Ho ^a   Jung, Jinkyung ^a   Lee, Jung Min ^a   Kim, Nam Jung ^a   Han, Young Taek ^a   Yun, Hwayoung ^a   Lee, Sujin ^a   Lee, Geumwoo ^a   Lee, Seungbeom ^a   Lee, Ju Sung ^a   Cha, Jong Ho ^a   Park, Ji Hyeon ^a   Park, Ji Won ^a   Lee, Su Chan ^a   Kim, Sang Geon ^a   Kim, Jeong Hun ^a,b   Lee, Ho Young ^a   Kim, Kyu Won ^a   Suh, Young Ger ^a   more..

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 1 ( 1 METHOXY 2,2 DIMETHYL 2H CHROMEN 6 YL)PROPAN 1 ONE; 2 (3,4 DIMETHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 6 YL)ETHANONE; 2 (3,4 DIMETHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 6 YL)PROPAN 1 ONE; ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEGUELIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYO, NONMAMMALIAN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING; ROTENONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; ZEBRAFISH;

EID: 84871647827     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301488q     Document Type: Article

References (63)

1. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, F. U. Pathways of chaperone-mediated protein folding in the cytosol Nat. Rev. Mol. Cell Biol. 2004, 5, 781-791 (Pubitemid 39336272)
2. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer Nat. Rev. Cancer 2005, 5, 761-772 (Pubitemid 41400776)
3. Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic opportunity Mol. Cancer Ther. 2004, 3, 1021-1030 (Pubitemid 39199597)
4. Stepanova, L.; Leng, X. H.; Parker, S. B.; Harper, J. W. Mammalian p50(Cdc37) is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4 Gene. Dev. 1996, 10, 1491-1502 (Pubitemid 26260706)
5. Holt, S. E.; Aisner, D. L.; Baur, J.; Tesmer, V. M.; Dy, M.; Ouellette, M.; Trager, J. B.; Morin, G. B.; Toft, D. O.; Shay, J. W.; Wright, W. E.; White, M. A. Functional requirement of p23 and Hsp90 in telomerase complexes Genes Dev. 1999, 13, 817-826 (Pubitemid 29169841)
6. Munster, P. N.; Marchion, D. C.; Basso, A. D.; Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway Cancer Res. 2002, 62, 3132-3137 (Pubitemid 34602405)
7. Basso, A. D.; Solit, D. B.; Chiosis, G.; Giri, B.; Tsichlis, P.; Rosen, N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function J. Biol. Chem. 2002, 277, 39858-39866 (Pubitemid 35190971)
8. Isaacs, J. S.; Jung, Y. J.; Mimnaugh, E. G.; Martinez, A.; Cuttitta, F.; Neckers, L. M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1alpha-degradative pathway J. Biol. Chem. 2002, 277, 29936-29944
9. Beliakoff, J.; Bagatell, R.; Paine-Murrieta, G.; Taylor, C. W.; Lykkesfeldt, A. E.; Whitesell, L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors Clin. Cancer Res. 2003, 9, 4961-4971 (Pubitemid 37323303)
10. Eustace, B. K.; Sakurai, T.; Stewart, J. K.; Yimlamai, D.; Unger, C.; Zehetmeier, C.; Lain, B.; Torella, C.; Henning, S. W.; Beste, G.; Scroggins, B. T.; Neckers, L.; Ilag, L. L.; Jay, D. G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness Nat. Cell Biol. 2004, 6, 507-514 (Pubitemid 38786593)
11. Kim, J. H.; Yu, Y. S.; Park, K. H.; Kang, H. J.; Lee, H. Y.; Kim, K. W. Antiangiogenic effect of deguelin on choroidal neovascularization J. Pharmacol. Exp. Ther. 2008, 324, 643
12. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discovery 2007, 6, 273-286 (Pubitemid 46505878)
13. Pearl, L. H.; Prodromou, C. Structure and in vivo function of Hsp90 Curr. Opin. Struct. Biol. 2000, 10, 46-51 (Pubitemid 30099326)
14. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997, 89, 239-250 (Pubitemid 27199896)
15. Whitesell, L.; Mimnaugh, E. G.; Decosta, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat-shock protein Hsp90-PP60(v -src) heteroprotein complex-formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 8324-8328
16. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical and pharmacological evaluation of geldanamycin as an antitumor agent Cancer Chemother. Pharmacol. 1995, 36, 305-315
17. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity Invest. New Drugs 1999, 17, 361-373 (Pubitemid 30135903)
18. Schulte, T. W.; Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother. Pharmacol. 1998, 42, 273-279 (Pubitemid 28393843)
19. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin J. Med. Chem. 1999, 42, 260-266 (Pubitemid 29069861)
20. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin Cell Stress Chaperones. 1998, 3, 100-108 (Pubitemid 28327422)
21. Soga, S.; Kozawa, T.; Narumi, H.; Akinaga, S.; Irie, K.; Matsumoto, K.; Sharma, S. V.; Nakano, H.; Mizukami, T.; Hara, M. Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway J. Biol. Chem. 1998, 273, 822-828 (Pubitemid 28049172)
22. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. V. Development of radicicol analogues Curr. Cancer Drug Targets 2003, 3, 359-369 (Pubitemid 37128322)
23. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells Chem. Biol. 2001, 8, 289-299 (Pubitemid 32296118)
24. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase Bioorg. Med. Chem. 2002, 10, 3555-3564
25. Chiosis, G.; Rosen, N.; Sepp-Lorenzino, L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family Bioorg. Med. Chem. Lett. 2001, 11, 909-913 (Pubitemid 32226213)
26. Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of purine-scaffold small molecule inhibitors of Hsp90 Curr. Cancer Drug Targets 2003, 3, 371-376 (Pubitemid 37128323)
27. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90 Chem. Biol. 2004, 11, 787-797 (Pubitemid 38836895)
28. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins J. Natl. Cancer Inst. 2000, 92, 242-248 (Pubitemid 30099783)
29. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone J. Biol. Chem. 2000, 275, 37181-37186 (Pubitemid 32002137)
30. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90 J. Am. Chem. Soc. 2006, 128, 15529-15536 (Pubitemid 44876029)
31. Zhang, H.; Yang, C.; Choi, D. Characterization of a novel Hsp90 inhibitor with an extended duration of action Proc. Natl. Acad. Sci. U.S.A. 2003, 11-14
32. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J. Clin. Oncol. 2005, 23, 4152
33. Clark, E. P. A relation between rotenone, deguelin and tephrosin Science 1931, 73, 17-18
34. Travis, L.; Hill, D. A.; Dores, G. M.; Gospodarowicz, M.; van Leeuwen, F. E.; Holowaty, E.; Glimelius, B.; Andersson, M.; Wiklund, T.; Lynch, C. F.; Van't Veer, M. B.; Glimelius, I.; Storm, H.; Pukkala, E.; Stovall, M.; Curtis, R.; Boice, J. D., Jr.; Gilbert, E. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease JAMA, J. Am. Med. Assoc. 2003, 290, 465-475 (Pubitemid 37430500)
35. Lee, H. Y.; Oh, S. H.; Woo, J. K.; Kim, W. Y.; Van Pelt, C. S.; Price, R. E.; Cody, D.; Tran, H.; Pezzuto, J. M.; Moriarty, R. M. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis J. Natl. Cancer Inst. 2005, 97, 1695-1699 (Pubitemid 41672236)
36. Lee, H. Y. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells Biochem. Pharmacol. 2004, 68, 1119-1124
37. Udeani, G. O.; Gerhauser, C.; Thomas, C. F.; Moon, R. C.; Kosmeder, J. W.; Kinghorn, A. D.; Moriarty, R. M.; Pezzuto, J. M. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid Cancer Res. 1997, 57, 3424-3428 (Pubitemid 27355487)
38. Udeani, G. O.; Zhao, G. M.; Shin, Y. G.; Kosmeder, Ii, J. W.; Beecher, C. W. W.; Kinghorn, A. D.; Moriarty, R. M.; Moon, R. C.; Pezzuto, J. M. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats Cancer Chemother. Pharmacol. 2001, 47, 263-268 (Pubitemid 32640762)
39. Oh, S. H.; Woo, J. K.; Yazici, Y. D.; Myers, J. N.; Kim, W. Y.; Jin, Q.; Hong, S. S.; Park, H. J.; Suh, Y. G.; Kim, K. W. Structural basis for depletion of heat shock protein 90 client proteins by deguelin J. Natl. Cancer Inst. 2007, 99, 949-961 (Pubitemid 47073501)
40. Kim, W. Y.; Chang, D. J.; Hennessy, B.; Kang, H. J.; Yoo, J.; Han, S. H.; Kim, Y. S.; Park, H. J.; Seo, S. Y.; Mills, G.; Suh, Y. G.; Lee, H. Y. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy Cancer Prev. Res. 2008, 1, 577-587
41. Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90 J. Biomol. Screening 2004, 9, 375-381
42. Howes, R.; Barril, X.; Dymock, B. W.; Grant, K.; Northfield, C. J.; Robertson, A. G. S.; Surgenor, A.; Wayne, J.; Wright, L.; James, K. A fluorescence polarization assay for inhibitors of Hsp90 Anal. Biochem. 2006, 350, 202-213 (Pubitemid 43332820)
43. Hieronymus, H.; Lamb, J.; Ross, K. N.; Peng, X. P.; Clement, C.; Rodina, A.; Nieto, M.; Du, J. Y.; Stegmaier, K.; Raj, S. M.; Maloney, K. N.; Clardy, J.; Hahn, W. C.; Chiosis, G.; Golub, T. R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators Cancer Cell 2006, 10, 321-330 (Pubitemid 44512193)
44. Brandt, G. E. L.; Schmidt, M. D.; Prisinzano, T. E.; Blagg, B. S. J. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships J. Med. Chem. 2008, 51, 6495-6502
45. Caboni, P.; Sherer, T. B.; Zhang, N.; Taylor, G.; Na, H. M.; Greenamyre, J. T.; Casida, J. E. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease Chem. Res. Toxicol. 2004, 17, 1540-1548 (Pubitemid 39532322)
46. Anzeveno, P. B. Rotenoid interconversion. Synthesis of deguelin from rotenone J. Org. Chem. 1979, 44, 2578-2580
47. Lin, W. M.; Tryder, N.; Su, F.; Zercher, C. K.; Jasinski, J. P.; Butcher, R. J. Stereocontrolled formation of ketomethylene isosteres through tandem chain extension reactions J. Org. Chem. 2006, 71, 8140-8145 (Pubitemid 44571820)
48. Mohamed, S. E. N.; Thomas, P.; Whiting, D. A. Synthesis of the phytoalexin (±)-phaseollin: 3-phenylthiochromans as masked 2 H -chromenes and o -prenyl phenols J. Chem. Soc., Perkin Trans. 1987, 1, 431-437
49. Henry, G. E.; Jacobs, H. A short synthesis of 5-methoxy-2, 2-dimethyl-2 H -1-benzopyran-6-propanoic acid methyl ester Tetrahedron 2001, 57, 5335-5338 (Pubitemid 32530873)
50. Adler, M. J.; Baldwin, S. W. Direct, regioselective synthesis of 2, 2-dimethyl-2 H -chromenes. Total syntheses of octandrenolone and precocenes I and II Tetrahedron Lett. 2009, 50, 5075-5079
51. Garcia, J.; Barluenga, S.; Beebe, K.; Neckers, L.; Winssinger, N. Concise modular asymmetric synthesis of deguelin, tephrosin and investigation into their mode of action Chem.-Eur. J. 2010, 16, 9767-9771
52. Hodgson, H. H. The Sandmeyer reaction Chem. Rev. 1947, 40, 251-277
53. Chang, J.; Guo, X.; Cheng, S.; Guo, R.; Chen, R.; Zhao, K. Efficient synthesis of [gamma]-DDB Bioorg. Med. Chem. Lett. 2004, 14, 2131-2136
54. Olivera, R.; SanMartin, R.; Churruca, F.; Dominguez, E. Revisiting the Ullmann-ether reaction: a concise and amenable synthesis of novel dibenzoxepino[4,5- d ]pyrazoles by intramolecular etheration of 4,5-(o, o ′-halohydroxy)arylpyrazoles J. Org. Chem. 2002, 67, 7215-7225 (Pubitemid 35176368)
55. Adams, H.; Gilmore, N. J.; Jones, S.; Muldowney, M. P.; von Reuss, S. H.; Vemula, R. Asymmetric synthesis of corsifuran A by an enantioselective oxazaborolidine reduction Org. Lett. 2008, 10, 1457-1460
56. Kuwabe, S.; Torraca, K. E.; Buchwald, S. L. Palladium-catalyzed intramolecular C-O bond formation J. Am. Chem. Soc. 2001, 123, 12202-12206 (Pubitemid 33136057)
57. 2). Formation and application to organic synthesis J. Am. Chem. Soc. 1965, 87, 1353-1364
58. Chang, D. J.; Nahm, K.; Park, B. S. Reversed diastereoselectivity in the Yang photocyclization upon introducing a cyclopropyl group at the alpha position to carbonyls Tetrahedron Lett. 2002, 43, 4249-4252 (Pubitemid 34603196)
59. Kim, H.; Kim, T. G.; Hahn, J.; Jang, D. J.; Chang, D. J.; Park, B. S. Photolysis dynamics of cyclopropyl and oxiranyl aryl ketones: drastic ring-activation effect of oxygen J. Phys. Chem. A 2001, 105, 3555-3563
60. Vicario, J. L.; Badia, D.; Dominguez, E.; Carrillo, L. A new general method for the asymmetric synthesis of 4-alkyl-3-aryl-1,2,3,4- tetrahydroisoquinolines J. Org. Chem. 1999, 64, 4610-4616
61. Suh, Y. G.; Kim, N. J.; Koo, B. W.; Lee, K. O.; Moon, S. H.; Shin, D. H.; Jung, J. W.; Paek, S. M.; Chang, D. J.; Li, F. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor a and g dual agonists J. Med. Chem. 2008, 51, 6318-6333
62. Agranat, I.; Caner, H.; Caldwell, J. Putting chirality to work: the strategy of chiral switches Nat. Rev. Drug Discovery 2002, 1, 753-768 (Pubitemid 37361560)
63. Zon, L. I.; Peterson, R. T. In vivo drug discovery in the zebrafish Nat. Rev. Drug Discovery 2005, 4, 35-44 (Pubitemid 40109588)